Lv3
268 积分 2026-07-06 加入
Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor
4天前
已完结
Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy
5天前
已完结
Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma
5天前
已完结
Molecular and Immune Correlates of Lymphocyte Activation Gene-3 Expression in Renal Cell Carcinoma
5天前
已完结
Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial
5天前
已完结
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
5天前
已完结
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
5天前
已完结
PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
5天前
已完结
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
5天前
已完结
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
5天前
已完结
皖公网安备34019202002308
